Literature DB >> 2213163

Clonal origin of pituitary adenomas.

L B Jacoby1, E T Hedley-Whyte, K Pulaski, B R Seizinger, R L Martuza.   

Abstract

Benign pituitary adenomas are among the most common neurosurgical tumors and account for a diversity of clinical syndromes due to their hormone content and release. To determine whether these tumors arise from a single cell or multiple cells, the authors studied X chromosome inactivation in deoxyribonucleic acid (DNA) isolated from pituitary adenomas in women. Tumors of three different hormonal subtypes were examined. One tumor contained cells immunoreactive for prolactin and human growth hormone; one tumor contained foci immunoreactive for the beta-subunits of luteinizing hormone and follicle-stimulating hormone; and the third tumor had no immunoreactive prolactin, human growth hormone, beta-subunits of thyroid-stimulating hormone, luteinizing hormone, or follicle-stimulating hormone, or the alpha-subunit. Analysis of the DNA revealed that, in each of the three pituitary tumors, one X chromosome was active in all cells and one X chromosome was inactive, indicating that each of these tumors was monoclonal in origin. It is concluded that clinically evident pituitary tumors arise from a genetic mutation in a single cell.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213163     DOI: 10.3171/jns.1990.73.5.0731

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  16 in total

1.  Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex.

Authors:  S J Díaz-Cano; M de Miguel; A Blanes; R Tashjian; H Galera; H J Wolfe
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  A case of pituitary somatotroph adenoma with concomitant secretion of growth hormone, prolactin, and adrenocorticotropic hormone--an adenoma derived from primordial stem cell, studied by immunohistochemistry, in situ hybridization, and cell culture.

Authors:  A Matsuno; T Sasaki; T Mochizuki; T Fujimaki; N Sanno; Y Osamura; A Teramoto; T Kirino
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  A heritable predisposition to pituitary tumors.

Authors:  William T Couldwell; Lisa Cannon-Albright
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

4.  Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.

Authors:  Paweena Chunharojrith; Yuki Nakayama; Xiaobing Jiang; Rachel E Kery; Jun Ma; Cristine S De La Hoz Ulloa; Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2015-08-15       Impact factor: 4.102

5.  Gonadotropin-releasing hormone receptor mRNA expression by human pituitary tumors in vitro.

Authors:  J M Alexander; A Klibanski
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

6.  Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia.

Authors:  A Arnold; M F Brown; P Ureña; R D Gaz; E Sarfati; T B Drüeke
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 7.  Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma.

Authors:  Yunli Zhou; Xun Zhang; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2013-09-11       Impact factor: 4.102

8.  Composite somatotroph--ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma.

Authors:  N Mazarakis; G Kontogeorgos; K Kovacs; E Horvath; N Borboli; G Piaditis
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

Review 9.  Pituitary adenomas: historical perspective, surgical management and future directions.

Authors:  Debebe Theodros; Mira Patel; Jacob Ruzevick; Michael Lim; Chetan Bettegowda
Journal:  CNS Oncol       Date:  2015-10-26

Review 10.  Collision sellar lesions: experience with eight cases and review of the literature.

Authors:  Maria Koutourousiou; George Kontogeorgos; Pieter Wesseling; Andre J Grotenhuis; Andreas Seretis
Journal:  Pituitary       Date:  2009-06-24       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.